S932 زعفران: درمان کمکی امیدوارکننده در کولیت اولسراتیو – کارآزمایی ارزیابی نتایج بالینی و آزمایشگاهی

کولیت اولسروز یک بیماری مزمن التهابی روده است که با التهاب مکرر مخاط روده بزرگ همراه است. درمان‌های ایمنوساپرسیو موجود عوارض جانبی دارند و به دنبال گزینه‌های درمانی جایگزین هستیم. تحقیقات اخیر نقش مداخلات غذایی و تغذیه‌ای به عنوان درمان‌های کمکی را بررسی کرده‌اند. زعفران، ادویه‌ای از گل Crocus sativus، خواص ضدالتهابی و آنتی‌اکسیدانی امیدوارکننده‌ای در مدل‌های پیش‌بالینی IBD نشان داده است.

این مطالعه پاسخ‌های بالینی و آزمایشگاهی بیماران کولیت ملایم تا متوسط را به افزودن زعفران به درمان معمول ارزیابی کرد. ۲۷ بیمار با سطح کلپروتکتین مدفوع بالای ۵۰ به سه گروه (پلاسبو، دوز پایین و دوز بالا زعفران) تقسیم شدند و برای ۸ هفته تحت درمان قرار گرفتند. نمرات بالینی و آزمایشگاهی در گروه دوز بالا بهبود معناداری داشت. هیچ عارضه جانبی گزارش نشد. نتایج نشان داد زعفران به عنوان درمان کمکی می‌تواند اثربخشی درمان را افزایش داده و وابستگی به داروهای ایمنوساپرسیو را کاهش دهد.

Introduction: Ulcerative Colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by recurrent inflammation of the colonic mucosa. The existing immunosuppressive treatments for UC have adverse side effects, leading to the exploration of alternative therapeutic options. In recent years, there has been growing interest in the potential role of dietary and nutritional interventions as adjuvant treatments for UC. Saffron, a spice derived from the Crocus sativus flower, has shown promising anti-inflammatory and anti-oxidant properties in preclinical models of IBD.

This study aims to evaluate the clinical and laboratory response of patients with mild to moderate UC to the addition of saffron to conventional treatment. Methods: This clinical trial took place at Sadoughi Hospital, a university-based facility. Twenty-seven patients .18 years with UC in remission and fecal calprotectin levels .50 mg/mg were randomly assigned to 1 of 3 arms: placebo, low-dose (25 mg), or high-dose saffron (50mg), 2 times a day for 8 weeks in addition to their standard treatment. Laboratory markers including hemoglobin, platelet levels, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and fecal calprotectin along with clinical data such as simple clinical colitis activity index (SCCAI), partial Mayo score, and Hamilton anxiety score (HAMA) were recorded at baseline and completion of treatment.

The study was approved by Ethical committee, including obtaining informed consent. Univariant analysis was used to compare the post treatment outcomes to their baseline. Results: All 27 patients successfully completed the study. The basic characteristics of the participants in the different treatment groups are summarized in Table 1. While the HAM-A score and fecal calprotectin significantly improved in both the high (P50.001 and 0.009, respectively) and low dose groups (P5 0.01 and 0.039, respectively), the SCCAI (P50.04), Partial Mayo score (P50.01), and CRP (P 50.001) showed significant improvement only in the high dose group compared to their baseline (Table 1). No adverse drug events were reported during the study (Figure 1). Conclusion: Saffron demonstrates promising results in UC, improving both clinical and laboratory outcomes. As an adjuvant treatment, it has the potential to enhance therapeutic efficacy and minimize the reliance on immunosuppressant drugs that associate with side effects.